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Signal transductiona b s t r a c t
Cross-communication between GPCRs and TKRs represents a mechanism to amplify the information
exchange throughout the cell. We show that WKYMVm, an FPR2 agonist, induces the phosphoryla-
tion of Y1313/Y1349/Y1356 residues of c-Met and triggers some of the molecular responses elicited
by c-Met/HGF binding, such as STAT3, PLC-c1/PKCa and PI3K/Akt pathways. The critical role of
NADPH oxidase-dependent superoxide generation in this cross-talk mechanism is supported by
the ﬁnding that blockade of NADPH oxidase function prevents c-Met trans-phosphorylation and
the downstream signalling cascade. These results highlight the function of FPR2 to activate a inter-
connected signalling network and suggest novel possibilities for therapeutic interventions.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Eukaryotic cells have developed highly efﬁcient mechanisms of
receptor-mediated cell communication to coordinate and integrate
extracellular signals. The formyl-peptide receptors FPR1, FPR2 and
FPR3 belong to the G protein-coupled receptors (GPCR) super-fam-
ily and are coupled to pertussis toxin (PTX)-sensitive Gi proteins
[1]. FPR1 is efﬁciently activated by N-formyl-methionyl-leucyl-
phenylalanine, whereas FPR2 shows an higher binding efﬁciency
for WKYMVm [2]. The expression of these receptors has been dem-
onstrated in several cell types [3] and their important biological
functions are supported by the identiﬁcation of high afﬁnity
host-derived agonists. [4–6].
Despite GPCRs lack intrinsic tyrosine kinase activity, tyrosine
phosphorylation of a tyrosine kinase receptor (TKR) occurs in re-
sponse to binding of speciﬁc agonists of several such receptors.
GPCR ligands increase tyrosine phosphorylation of TKRs either by
increasing the kinase activity or by inhibiting an associated protein
tyrosine phosphatase [7]. These events are mediated by reactive
oxygen species (ROS) whose concentration increases transiently
in cells stimulated with GPCR agonists. Several evidence support
the role of ROS in TKR transactivation. For instance, in human lungcancer cells stimulation of FPR2 by WKYMVm induces ROS-depen-
dent EGFR tyrosine phosphorylation [8] and in human carcinoma
cells ROS mediate c-Met transactivation by GPCRs [9]. The deliber-
ated and regulated generation of ROS is catalyzed by enzymes that
belong to NADPH oxidase (Nox) family, constituted by membrane
and cytosolic components. Phosphorylation of the regulatory cyto-
solic protein p47phox on several serine residues is associated with
oxidase activation [10].
The c-Met tyrosine kinase receptor (c-Met) is a cell surface
receptor for hepatocyte growth factor (HGF) [11]. Following HGF
binding, the tyrosine kinase domain of c-Met undergoes trans-
phosphorylation on the Y1234 and Y1235 residues in the activa-
tion loop [12]. Kinase activation by autophosphorylation leads to
the subsequent phosphorylation of Y1349 and Y1356 residues in
the C-terminal multifunctional docking site, resulting in the activa-
tion of c-Met signalling [12]. Previously, we demonstrated that
PNT1A cells express a functional c-Met and cell exposure to NK1,
a splice variant of HGF, induces the phosphorylation of Y1313/
Y1349/Y1356 residues of c-Met which provide docking sites for
the activation of intracellular signalling pathways [13].
The aims of this study were to analyze the cross-talk between
FPR2 and c-Met in PNT1A cells and to identify intracellular signal-
ling cascades triggered by the WKYMVM-mediated activation of
HGF receptor. We show that stimulation of FPR2 by its agonist re-
sults in the phosphorylation of tyrosine 1313/1349/1356 residues
of c-Met and promotes some of the molecular responses elicited
by the binding of HGF to its receptor.
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2.1. Antibodies and chemicals
The WKYMVm and WRWWWW (WRW4) peptides were syn-
thesized and HPLC-puriﬁed by PRIMM (Milan, Italy). SDS–PAGE re-
agents were from Bio-Rad (Hercules, CA, USA). Protein A/G Plus
agarose, anti-active phosphorylated ERK1/2, anti-tubulin, anti-
p47phox, anti-p22phox, anti-FPR2, anti-cMet, anti-STAT3, anti-cyclin
A, anti-p-Y, anti-phospho-cMet(Y1313), anti-phospho-
cMet(Y1349), anti-PLC-c1, anti-phospho-PLC-c1, anti-PKCa, anti-
PKCd, anti-PKCe and anti-rabbit antibodies were from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-phospho-STAT3(-
Tyr705), anti-phospho-STAT3(Ser727), anti-phospho-PI3K(p85)
and anti-phospho-Akt(S473) were from Cell Signalling Technology
(Danvers, MA, USA). Anti-phospho-cMet(Y1356) was purchased
from Abnova (Walnut, CA, USA). Protein A-horseradish peroxidase
and anti-mouse Ig-horseradish peroxidase were from Amersham
Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK).
PD098059 and SU11274 were from Calbiochem (La Jolla, CA,
USA). Anti-phospho-Ser antibody, PTX, apocynin, phorbol 12-myr-
istate 13-acetate (PMA), Wortmannin and LY294002 were from
Sigma (St. Louis, MO, USA). p22phox siRNA (SI03078523) and nega-
tive control siRNA (SI03650318) were purchased from Qiagen
(Hiden, Germany). c-Met siRNA (L-003156-00), FPR2 siRNA (L-
005140-00) and a negative scrambled control (D-001810-10) were
obtained from Dharmacon (Lafayette, CO, USA).Fig. 1. FPR2 is a functional receptor in PNT1A cells. (A) Membrane (Membr.), cytoplasm
FPR2 antibody. (B) cDNAs from PNT1A cells, PMN and monocytes (mon.) were coampliﬁ
indicated times, or (D) preincubated with PTX or WRW4 before stimulation. Whole lysat
phosphorylation was detected by using an a-p-Ser antibody. An a-p47phox antibody serv
SOD-sensitive rate of reduction of cytochrome c. ⁄P < 0.05 compared with unstimulated2.2. Cell culture
PNT1A and primary prostate epithelial cells were purchased
from ATCC (Rockville, MD, USA) and were grown in RPMI supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
100 U/ml penicillin, 100 lg/ml streptomycin and 1% L-glutamine.
Cells were cultured until they reached 80% conﬂuence, starved in
serum-free RPMI for 24 h and stimulated with WKYMVm at the ﬁ-
nal concentration of 10 lM for different times, as indicated in the
ﬁgures. In other experiments, serum-deprived cells were preincu-
bated with 50 lM PD098059 for 90 min, or 100 ng/ml PTX for
16 h, or 2 lM SU11274 for 16 h, or 50 lM LY294002 for 1 h, or
0.5 lM Wortmannin for 1 h, or 100 lM apocynin for 2 h, or
10 lM WRW4 for 15 min, before stimulation with 10 lM
WKYMVm for 2 min. In short interfering RNA experiments
4  105 cells were incubated for 12 h with 5 nM siRNAs in RPMI
containing 10% FBS in the presence of 20 ll HiPerFect (Qiagen,
Hiden, Germany). Cells were then serum-deprived for 24 h and
stimulated with WKYMVm. PNT1A cells were also stimulated with
10 ng/ml PMA for different times as indicated in the ﬁgure.
2.3. Western blot and immunoprecipitation analysis
Cells were stimulated with WKYMVm in the presence or ab-
sence of the appropriate amount of speciﬁc inhibitors and rinsed
with cold phosphate-buffered saline. Cell lysates were puriﬁed as
previously described [8] and proteins concentration was deter-
mined by a Bio-Rad protein assay (BioRad, Hercules, CA, USA). Nu-ic (Cyt.) and whole (Tot.) lysates (50 lg) were analyzed by western blot with an a-
ed by using FPRs and GAPDH primers; (C) Cell were exposed to WKYMVm for the
es (1 mg) were immunoprecipitated with an a-p47phox antibody and p47phox serine
ed as a control for protein loading. (E) Superoxide production was determined as the
cells.
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with a Qproteome kit (Qiagen, Hiden, Germany) and with a Mem-
PER Kit (Thermo Scientiﬁc, Rockford, USA), respectively, accordingFig. 2. FPR2 activation results in c-Met trans-phosphorylation. (A) Whole lysates (800 l
tyrosine phosphorylation level was detected with an a-pY antibody. PNT1A (B) or prim
times. (D) PNT1A cells were preincubated with PTX or WRW4 or SU11274, or (E) with siR
p22phox (p22phox siRNA) or with apocynin, before stimulation. A negative control siRNA
PMA for the indicated times. Whole lysates (50 lg) were subjected to immunoblotting a
with a-p-cMet(1313), a-p-cMet(1349) or a-p-cMet(1356) antibodies. ⁄P < 0.05, P < 0.05to the manufacturer’s instructions. Western blot analysis was per-
formed as previously described [8]. The expression of targeted pro-
teins was detected by an ECL chemiluminescence reagent kitg) from PNT1A cells were immunoprecipitated with an a-cMet antibody and c-Met
ary prostate epithelial cells (C) were stimulated with WKYMVm for the indicated
NAs against FPR2 (FPR2 siRNA) or c-Met (c-Met siRNA), or (F) with a siRNA against
(NC siRNA) was included in the experiments. (G) PNT1A cells were stimulated with
nalysis and phosphorylation of Y1313/Y1349/Y1356 residues of c-Met was detected
and ^P < 0.05 compared with unstimulated cells.
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phy. In immunoprecipitation experiments, cell lysates containing
equal amounts of proteins were incubated with 3 lg of either
anti-cMet or anti-p47phox antibody [8]. Proteins were resolved on
a 10% SDS–PAGE and phosphorylated protein levels were quantita-
tively estimated by densitometry using a Discover Pharmacia
scanner.
2.4. Assay of superoxide production and RT-PCR analysis
Superoxide production assay, RNA puriﬁcation and RT-PCR
analysis were performed as previously described [8]. The following
primers were designed to amplify human FPRs coding regions:
(FPR1) 50-GACCACAGCTGGTGAACAGT-30 and 50-GATGCAGGACGC
AAACACAG-30; (FPR2) 50-GGATTTGCACCCACTGCATTT-30 and 50-
ATCCAAGGTCCGACGATCAC-30; (FPR3) 50-GAGTTGCTCCACAGGAA
TCCA-30 and 50- ATAGGCACGCTGAAGCCAAT-30. These primers gen-
erate 474, 528 and 760 bp fragments, respectively.
2.5. Statistical analysis
All the presented data are expressed as means ± S.D. and are
representative of three or more independent experiments. Statisti-
cal analyses were assessed by Student’s t test for paired data. Re-
sults were considered signiﬁcant at P < 0.05.
3. Results
3.1. PNT1A cells express a functional FPR2 receptor
We ﬁrst analyzed the expression of FPR2 in membrane, cyto-
plasmic and total proteins puriﬁed by PNT1A cells. We detectedFig. 3. FPR2 activation triggers STAT3 pathway. (A) PNT1A cells were stimulated for the i
with a-pSTAT3(Y705) or a-pSTAT3(S727) antibodies. An a-STAT3 antibody served as a c
extracts (50 lg) with an a-STAT3 antibody. The same ﬁlter was reprobed with an a-cyclin
FPR2 siRNA or c-Met siRNA, or (E) with a p22phox siRNA or apocynin, before WKYMVm
subjected to immunoblotting analysis with a-p-STAT3(Y705) or a-p-STAT3(S727) antibthe presence of the band corresponding to FPR2 protein at the ex-
pected molecular size on membrane extracts by using an a-FPR2
antibody (Fig. 1A). By RT-PCR we detected FPR2 but not FPR1 and
FPR3, providing the ﬁrst evidence of FPR2 expression in these cells.
(Fig. 1B). In IMR90 ﬁbroblasts and in human lung cancer cells,
stimulation of FPR2 with 10 lM WKYMVm induces p47phox phos-
phorylation, which is considered the key event for NADPH oxi-
dase-dependent superoxide generation [8,14]. In immunoblot
experiments we observed that p47phox results phosphorylated on
serine residues within the ﬁrst 2 min of stimulation (Fig. 1C) and
that preincubation with PTX or with the FPR2 antagonist WRW4
peptide, signiﬁcantly prevents p47phox serine phosphorylation
(Fig. 1D). Furthermore, stimulation of FPR2 by WKYMVm induces
NADPH oxidase-dependent superoxide generation with maximal
production occurring at 2 min (Fig. 1E), indicating that FPR2 is a
biologically functional receptor in PNT1A cells.
3.2. FPR2 activation promotes the phosphorylation of Y1313/Y1349/
Y1356 residues of c-Met
Cross-talk between GPCRs and TKRs plays an instrumental role
in orchestrating downstream signalling molecules. We analyzed
the ability of FPR2 to transactivate c-Met and, in immunoblot
experiments, we observed that stimulation with WKYMVm in-
duces the time-dependent phosphorylation of the HGF receptor
(Fig. 2A). In particular, the FPR2 agonist promotes the phosphory-
lation of Y1313/Y1349/Y1356 residues of c-Met within the ﬁrst
2 min which decreases after 5 min of stimulation, both in PNT1A
(Fig. 2B) and primary prostate epithelial cells (Fig. 2C). Further-
more, preincubation of PNT1A cells with the c-Met inhibitor
SU11274 or PTX or WRW4 (Fig. 2D), or with siRNAs against FPR2ndicated times with WKYMVm and speciﬁc phosphorylation of STAT3 was detected
ontrol for protein loading. (B) STAT3 nuclear translocation was analyzed on nuclear
A antibody. (C) Cells were preincubated with PTX or SU11274 orWRW4, or (D) with
stimulation. A NC siRNA was included in the experiments. Proteins (50 lg) were
odies. P < 0.05 and ⁄P < 0.05 compared with unstimulated cells.
Fig. 4. FPR2-induced c-Met transactivation generates speciﬁc docking sites for PLC-
c1. (A) Proteins were puriﬁed from PNT1A cells exposed to WKYMVm for the
indicated times, or (B) preincubated with PTX or SU11274 or WRW4, before
stimulation. Fifty micrograms of lysates were analyzed with an a-pPLC-c1(Y783)
antibody. (C) Translocation of PKC isoforms was analyzed on membrane extracts
(30 lg) with a-PKCa or a-PKCd or a-PKCe antibodies. (D) Cells were preincubated
with PTX, or SU11274 or WRW4 before stimulation and 30 lg of puriﬁed
membrane proteins were analyzed with an a-PKCa antibody. The same ﬁlter was
reprobed with an a-cMet antibody.
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icant reduction in the phosphorylation level of these tyrosines.
Oxidation and/or reduction of cysteine sulfhydryl groups of
phosphotyrosine phosphatases (PTPases) tightly controls the activ-
ity of TKRs. Nox family is considered the main cytosolic source of
ROS [10] which can contribute to TKR transactivation by inhibiting
a PTPase activity [15] and, in turn, shifting the equilibrium state of
TKR from non-phosphorylated to phosphorylated. We preincu-
bated cells with the NADPH-oxidase-speciﬁc inhibitor apocynin
or with a siRNA against p22phox before WKYMVm stimulation,
and we observed that blockade of NADPH oxidase function pre-
vents FPR2-induced phosphorylation of Y1313/Y1349/Y1356 resi-
dues of c-Met (Fig. 2F).
We also incubated cells with PMA, an oxidase inducer, and we
observed that it promotes the phosphorylation of Y1349 and
Y1356 residues, but not of Y1313 residue, only after 5 min and
with a kinetic different from that induced by FPR2 stimulation
(Fig. 2G). This suggests that FPR2-mediated ROS production plays
a crucial role in this cross-talk mechanism.
3.3. FPR2/c-Met cross-talk triggers STAT3 pathway
The single multifunctional docking site located in the C-termi-
nus of the HGF receptor contains the sequence Y1349VHVNATY1356-
VNV, which provides binding sites for a variety of SH2-containing
signal transducers and effectors [16]. STAT3 binds to the sequence
following the phosphorylated Y1356 residue [17] and its association
with c-Met results in the phosphorylation of a conserved tyrosine
residue (Y705), which is required for promoting the dimerization
of STAT3. Activated STAT3 is then translocated in the nucleus
where it acts as a transcriptional factor. Full transcriptional activity
and DNA binding capacity are manifested only when the serine 727
residue of STAT3 is also phopshorylated.
In time-dependent western blot experiments, we observed that
WKYMVm induces the rapid phosphorylation of Y705 and S727
residues of STAT3 (Fig. 3A), as well as the nuclear translocation
of activated STAT3 (Fig. 3B). We also preincubated cells with PTX
or WRW4 or SU11274 (Fig. 3C), or with siRNAs against FPR2 or
c-Met (Fig. 3D), and we observed that these treatments prevent
the WKYMVm-induced activation of STAT3. Furthermore, we
blockaded NADPH oxidase function by pretreating cells with
apocynin or with a siRNA against p22phox and we observed that
FPR2-induced phosphorylation of Y705 and S727 residues of STAT3
was prevented (Fig. 3E).
3.4. FPR2-induced c-Met trans-phosphorylation generates speciﬁc
docking sites for PLC-c1
Signal transducers that bind sequences surrounding tyrosines
1349 and 1356 residues in c-Met can interact with the receptor
either directly or indirectly through the scaffolding protein Gab1,
which represents the key coordinator of the cellular responses to
c-Met [18]. After the interaction with the receptor, Gab1 becomes
phosphorylated on several tyrosine residues that, in turn, recruit a
number of signalling effectors, including PLC-c1 which can weakly
bind c-Met also directly [18]. We analyzed PLC-c1 activation in
WKYMVm-stimulated PNT1A cells and we observed in time-course
experiments that the FPR2 agonist induces PLC-c1 activation with
maximal phosphorylation of Y783 residue occuring at 2 min
(Fig. 4A). PLC-c1(Y783) phosphorylation is prevented by preincu-
bation with PTX or WRW4 or SU11274, before WKYMVm stimula-
tion (Fig. 4B). We also analyzed the PKC isoforms activated as a
consequence of the hydrolysis of phosphatidylinositol-4-5-bis-
phosphate by PLC-c1, by analyzing the cellular partitioning of
PKC isozymes in growth-arrested and WKYMVm-stimulated cells.
In response to the FPR2 agonist, of the seven PKC isoenzymes thatwe examined (data not shown) only PKCa translocates to the
membrane fraction and a signiﬁcant increase in the amount was
detected within 2 min of exposure to WKYMVm (Fig. 4C). In con-
trast, no translocation of PKCd and PKCe was observed (Fig. 4C).
Furthermore, the Gi protein speciﬁc inhibition, or a speciﬁc FPR2
antagonist, or an inhibitor of c-Met kinase activity, completely pre-
vents PKCa activation (Fig. 4D), suggesting that it depends on
FPR2-dependent c-Met phosphorylation.
3.5. FPR2-induced activation of the multifunctional docking site of c-
Met triggers PI3K/Akt pathway
Nine domains of Gab1 containing a single tyrosine are phos-
phorylated in vitro by HGF and three of these tyrosines (Y458/
Y473/Y590) bind the p85 regulatory subunit of PI3K [18]. In HGF
receptor there is also an other recognition motif (Y1313EVM) which
can represent a potential binding site for PI3K [19]. In immuno-
blotting experiments we observed that WKYMVm induces
PI3K(p85) phosphorylation within 2 min of stimulation (Fig. 5A).
This is prevented by pretreating cells with PTX, or SU11274, or
WRW4, or apocynin (Fig. 5B). PI3K is the key component for the
Fig. 5. FPR2/c-Met cross-talk triggers the activation of PI3K/Akt pathway. (A and C) Cells were exposed with WKYMVm for the indicated times or (B) preincubated with PTX
or SU11274 or WRW4 or apocynin, or (D) with PTX or WRW4 or Wortmannin or LY294002 or SU11274, or (E) with FPR2 siRNA or c-Met siRNA, or (F) with a p22phox siRNA,
before stimulation. A NC siRNA was included in the experiments. Proteins (50 lg) were analyzed with (A and B) an a-pPI3K(p85) antibody, or (C, D, E and F) with an a-
pAkt(S473) antibody. An a-Tubulin antibody was used as a control of protein loading. ⁄P < 0.05 compared with unstimulated cells.
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3-phosphoinositides by PI3K enables the activation of Akt by phos-
phoinositide-dependent protein kinases 1 and 2, which phosphor-
ylate Akt at threonine 308 and serine 473 residues, respectively.
We analyzed PI3K(p85) activity by analyzing Akt phosphorylation
in response to FPR2 stimulation and the results showed that
WKYMVm induces Akt(S473) phosphorylation within the same
time frame as PI3K(p85) phosphorylation (Fig. 5C). The preincuba-
tion of cells with highly selective PI3K inhibitors or PTX or WRW4
or SU11274 (Fig. 5D), or with siRNAs against FPR2 or c-Met
(Fig. 5E), or with a siRNA against p22phox (Fig. 5F), signiﬁcantly pre-
vents WKYMVm-induced Akt(S473) phosphorylation.
4. Discussion
In this study, we demonstrate that FPR2 activation results in the
phosphorylation of critical tyrosines within the single multisub-
strate docking site of the HGF receptor, and that superoxide gener-ation by NADPH oxidase plays a crucial role in the trans-
phosphorylation mechanism. We also show that these phosphoty-
rosines provide binding sites for a variety of SH2-containing signal
transducers, promoting some of the molecular responses triggered
by the binding of HGF to its receptor (Fig. 6).
In fact, we observed STAT3 activation which, in response to HGF
stimulation, binds to the sequence following Y1356 residue of c-Met
and is required for branching morphogenesis. Our results show
that STAT3 activation is prevented by blockade of FPR2, c-Met or
Nox functions, suggesting that it is a part of the FPR2-dependent
signalling cascade and depends on Nox activity.
Phosphotyrosines 1349 and 1356 of c-Met provide docking sites
for the interaction with Shc, Src and Gab1, while Y1356 residue is
mainly responsible for recruitment of Grb2, PI3K and PLC-c to
the HGF receptor signalling complex [18]. Phosphorylated PLC-c1
(Y771/Y783/Y1254 residues) is associated to HGF receptor via
Gab1, and this interaction is required for HGF-mediated tubulo-
genesis [20]. We show that WKYMVm-induced FPR2/c-Met cross-
Fig. 6. Schematic representation of the WKYMVm-induced cross-talk between FPR2 and c-Met and of the critical role of superoxide generation by NADPH oxidase in the
trans-phosphorylation mechanism.
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due of PLC-c1 and, in turn, the activation of PKCa which is impli-
cated in many cellular functions elicited by GPCR activation.
The activation of PI3K/Akt pathway is considered the main sig-
nalling cascade required for the induction of cell scattering and
EMT [13]. Tyrosine 1313 residue of c-Met, within the Y1313EVM
motif, is a potential binding site for PI3K [19] and Y1356 residue is
primarly responsible for recruitment of PI3K to c-Met signalling
complex [18]. We show that FPR2-mediated c-Met activation in-
duces the time-dependent phosphorylation of PI3K(p85) and Akt,
and that siRNAs against FPR2, or c-Met, or p22phox completely pre-
vents Akt activation, suggesting that the activation of PI3K/Akt
pathway depends on FPR2/c-Met cross-talk and NADPH oxidase
activity.
Taken together these results suggest that in PNT1A cells FPR2/c-
Met cross-communication promotes the phosphorylation of criti-
cal tyrosine residues involved in many of the biological responses
triggered by the HGF receptor. This results in the formation of a
structural scaffold on HGF receptor for the assembly of a signalling
complex that resembles that formed in response to interaction of
c-Met with its ligand. The elucidation of the intracellular signal
transduction pathways that mediate the biological effects induced
by FPR2 agonists is of major importance because these studies may
identify potential targets and suggest novel strategies for thera-
peutic interventions.
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